Get access

Viral clearance using disposable systems in monoclonal antibody commercial downstream processing

Authors

  • Joe X. Zhou,

    Corresponding author
    1. Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008
    • Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008.
    Search for more papers by this author
  • Felix Solamo,

    1. Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008
    Search for more papers by this author
  • Tony Hong,

    1. Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008
    Search for more papers by this author
  • Michael Shearer,

    1. Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008
    Search for more papers by this author
  • Tim Tressel

    1. Department of Purification Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320; telephone: 805-3134065; fax: 805-4995008
    Search for more papers by this author

Abstract

Once highly selective protein A affinity is chosen for robust mAb downstream processing, the major role of polishing steps is to remove product related impurities, trace amounts of host cell proteins, DNA/RNA, and potential viral contaminants. Disposable systems can act as powerful options either to replace or in addition to polishing column chromatography to ensure product purity and excellent viral clearance power for patients' safety. In this presentation, the implementation of three disposable systems such as depth filtration, membrane chromatography, and nanometer filtration technology in a commercial process are introduced. The data set of viral clearance with these systems is presented. Application advantages and disadvantages including cost analysis are further discussed. Biotechnol. Bioeng. 2008;100: 488–496. © 2008 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary